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a contributor to reduce risk of cardiovascular, cerebrovascular, and renal disease.
This study aims to examine how the Part D affects medication adherence to ang-
iotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers
(ARBs) for dual eligibles. METHODS: This is a retrospective study with an unbal-
anced panel design utilizing Medicaid Analytic eXtract (MAX) data for 2004-2005
and Medicare data for 2006-2007. The study population was dual eligibles who had
at least one claim on ACEIs or/and ARBs in eight states. Medication adherence was
measured as a Proportion of Days Covered (PDC) in each year from 2004-2007 (Ob-
servation number69,039). A separate analysis was conducted for community
based residents (Observation number54,266) and for nursing home residents (Ob-
servation number14,773). RESULTS: Unadjusted PDCs showed little difference
between pre-Part D and post-Part D program. Community based residents had a
PDC of 0.775 under pre-Part D and 0.782 under post-Part D. For nursing home
residents, a PDC was 0.813 under pre-Part D and 0.796 under post-Part D. This
finding was also supported by the regression analyses: Although Part D program
was positively associated with medication adherence, this was statistically insig-
nificant (p0.05). Non-white status, hospitalization, prescription drug based risk
adjustment, and residence of states were negatively associated with medication
adherence, and all of them were significant (p0.05). CONCLUSIONS: Contrary to
concerns from the public that that Part D program, delivered through private plans,
may have some negative effect on prescription drug uses for dual eligibles com-
pared to Medicaid program, we found no negative effect from the Part D on medi-
cation adherence to ACEIs or/and ARBs for dual eligibles.
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OBJECTIVES:TheCenters forMedicare andMedicaid Services (CMS) funded several
demonstration projects in 2006 to examine the role of patient navigation (PN) pro-
gram in increasing cancer screening and improving treatment outcomes. CMS paid
monthly capitated fees for PN services in these projects. Using Medicare beneficia-
ries diagnosed with lung cancer as an example, we evaluated the above Medicare
policy. METHODS:We designed a Markov model to describe the nature history of
the disease after a lung cancer diagnosis and evaluated the PN program from
payer’s perspective. The model characterized clinical benefits of PN services as
reduction in the delay of treatment, and survival benefit from better coordinated
care. Using costs and health utility (derived from EQ-5D) data collected from the
case (with PN services) and control (usual care) groups at the demonstration site led
by MD Anderson Cancer Center, supplemented with information from the litera-
ture, we estimated the life-time costs and quality-adjusted life years (QALYs) for
the PN and usual care groups, with a 3% discount rate. We addressed uncertainties
associated with modeling parameters in one-way as well as probabilistic sensitiv-
ity analyses. RESULTS:Compared to usual care, PN services incurred high costs but
also yielded better outcomes. The incremental cost and effectiveness was $6,295
and 0.285 QALYs, respectively, resulting in an ICER of $22,108/QALY. One-way sen-
sitivity analysis indicated that findings were most sensitive to a parameter that
captured the increase in utilization due to more frequently interaction with the
health care system driven by PN services. CE-acceptability curve showed that the
probability that the PN program was cost-effective was 63% and 93% at a societal
willingness-to-pay of $50,000 and $100,000/QALY, respectively. CONCLUSIONS:
Our case study of lung cancer suggested that instituting PN program is cost-effec-
tive for Medicare. Future research should evaluate whether the same conclusion
held in other cancers.
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OBJECTIVES: The purpose of this study is to quantify the perioperative outcomes,
complications, and costs associated with posterior spinal fusion among Medicare
enrollees with spinal stenosis and spondylolisthesis using a national Medicare
claims database. METHODS: The 5% systematic sample of Medicare claims data
(2005-2009) was used to identify outcomes of patients who received posterior spi-
nal fusion (PSF) for a diagnosis of lumbar spinal stenosis (LSS) or spondylolisthesis.
Enrollees further required aminimum of 2 years’ follow-up, and claim history of at
least 12 months prior to surgery. RESULTS: A final cohort of 1,672 PSF patients was
included. 50.7%had LSS only; 10.2%had spondylolisthesis only; and 39.1%had both
LSS and spondylolisthesis. The average agewas 71.4, and the average length of stay
was 4.6 days. At 3months, 1 year, and 2 years post-operative, the incidence of spine
reoperation was 19.9%, 24.0%, and 28.0%, respectively, while readmission for com-
plications was 34.5%, 41.4%, and 47.9%, respectively. 45.2% of patients had either a
spine reoperation or post-op epidural injection due to continued pain at 2 years.
The average payment was $36,230 / $17,020, $46,840 / $31,350, and $61,610
/ $46,580 at 3 months, 1 year, and 2 years, respectively. CONCLUSIONS: Over
half of the PSF-treated patients in this study had LSS alone, and 32% of stenosis-
only patients underwent fusion, suggesting that factors other than spondylolisthe-
sis play a significant role in the decision to recommend spinal fusion in this elderly
population. One in 4 elderly fusion patients being treated for LSS or spondylolis-
thesis was reoperated on the spine within 2 years, and nearly 1 in 2 readmitted for
a surgery-related complication. This data highlights several areas where improve-
ments can be made in the effective delivery and cost of surgical care for patients
with spinal stenosis and spondylolisthesis.
PODIUM SESSION I:
HEALTH CARE RISK MANAGEMENT
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REAL-WORLD EVIDENCE ON THE EFFECTS OF STATIN-FIBRATE COMBINATION
THERAPY IN TYPE-2 DIABETES: THE ACTION TO CONTROL CARDIOVASCULAR
RISK IN DIABETES (ACCORD) TRIAL REDUX
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OBJECTIVES: The famed ACCORD-Lipid Trial found that simvastatin/fenofibrate
combination therapy (CT) provides no incremental cardiovascular risk reduction in
type 2 diabetese (T2D) over statinmonotherapy (MT). Yet, with sales over $1 billion,
fibrate use in the US does not appear to have slowed down. The inconsistency
between scientific evidence and clinical practice raises concern. There is dearth of
longitudinal studies with longer follow-up evaluating the efficacy of CT over MT.
This study replicates the ACCORD-Lipid trial using a 16-year longitudinal claims
database froma large US health plan.METHODS:This retrospective study included
patients enrolled between 1995 and 2010. ACCORD inclusion/exclusion criteria
were adopted, that required, among other things, T2D patients on statinwith base-
line A1C7.5 and aged 40 to 79. The two study cohorts, MT and CT, were identified
from pharmacy claims. At a minimum, patients must have 1-year baseline and
90-day follow-up periods. Cox proportional hazard models were used on propen-
sity-score-matched sample to estimate the hazard of major adverse cardiac event
(MACE). Secondary ACCORD outcomes, described below, were also assessed.
RESULTS: The study included 9711 patients (MT8383; CT1328) with average
follow-up of 3.2 years. An average patient in the sample was a White male aged 57
years from the South with annual household income of $40-49K. The two study
cohorts differed in demographics (female, ethnicity, income), baseline lipid panel
(HDL/LDL/triglyceride/HbA1c), and comorbid conditions. CT and MT patients did
not differ in MACE rate (hazard rate or HR1.19), and in all-cause death (HR1.09),
macrovascular event(HR0.89), cardiovascular death(HR0.87), coronary disease
event(HR1.22), non-fatal stroke(HR1.09) and CHF event(HR1.04), all with non-
significant p-values. CONCLUSIONS:We found that, compared to MT, CT may not
provide any additional cardiovascular risk reduction in T2D. Given that our data-
base represents a large commercially-insured US population, our findings appear
to genearalize ACCORD-Lipid trial results to real-world population.
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OBJECTIVES: Pulmonary exacerbations (PEx) lead to substantial morbidity in cystic
fibrosis (CF), and guidelines recommend chronicmedication including dornase alfa
and inhaled tobramycin. However PEx risk and medication use vary across pa-
tients. We aimed to develop a PEx risk score among CF patients not receiving
guideline-recommended chronic respiratory medications. METHODS: Patients
without evidence of dornase alfa or inhaled tobramycin use in an index year, de-
spite meeting guideline recommended criteria, were identified from the CF Foun-
dation Patient Registry (2002 to 2008). This sample was randomly split into 2/3 for a
development sample and 1/3 for a validation sample. A multivariable risk score
was developed to predict PEx requiring hospitalization or home IV treatment using
available patient characteristics. Its predictive performance was assessed in the
validation sample. RESULTS:Among 3,069 patient-years, 1,275 (42%) had PEx in the
subsequent year. The risk score included, in order of decreasing impact on PEx risk,
prior PEx, Pseudomonas aeruginosa, allergic bronchopulmonary aspergillosis, de-
pression, methicillin-resistant Staphylococcus aureus, cystic fibrosis-related diabe-
tes, Burkholderia cepacia, prior use of dornase alfa, bronchodilator use, prior use of
inhaled tobramycin and lower FEV1 %-predicted. Stratifying patients by risk score
in the validation sample identified actual risks ranging from 14% in the lowest
decile to 90% in the highest. The c-statisticwas 0.8.CONCLUSIONS:APEx risk score
for CF patients not receiving guideline-recommended chronic therapieswas devel-
oped and validated, and identified patients with a wide range of risk. This score
could identify high-risk patients in whom chronic therapies should be initiated or
continued.
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OBJECTIVES: Previous studies indicated a higher risk of mortality with use of typ-
ical antipsychotics compared to atypical agents in diverse study populations. The
current study examined the risk of all-cause mortality among elderly dual eligible
beneficiaries (Medicaid and Medicare) using typical and atypical antipsychotics.
METHODS: A retrospective cohort study design matched on propensity score was
conducted using Medicare and Medicaid Analytical eXtract (MAX) data from four
states. The study population included elderly dual eligible beneficiaries (aged 65
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years) who started antipsychotic treatment during July 1, 2001 and December 31,
2003. Antipsychotic users were followed for up to six months using an intent-to-
treat approach. Extended Cox proportional hazard regression model stratified on
matched pairs based on the propensity scorewas used to evaluate the comparative
risk of death among users of typical and atypical antipsychotic agents. RESULTS:
There were 84, 162 (42, 081 atypical and 42, 081 typical) users of antipsychotic
agents in the final matched cohort. The unadjusted mortality rate was 11.12% (4,
682) for atypical users and 15.01% (6, 318) for typical users. Results of Cox regression
suggest that, typical users were more likely to die compared to atypical users
[Hazard Ratio (HR) 1.59, 95% Confidence Interval (CI) 1.52-1.66]. The extended Cox
model revealed that the risk of death was greater with typical use during the initial
40 days of treatment [40days: HR 2.00, 1.86-2.15]. The difference in risk persisted
after 40 days of typical antipsychotic use [40-180 days: HR, 1.40, 1.32-1.47].
CONCLUSIONS: The use of typical antipsychotic agents was associated with short-
term and long-term risks of mortality among elderly dual eligible beneficiaries
compared to atypical use. Given the underlying poor health status of dual eligible
beneficiaries, the study findings suggest that the use of typical agents needs to be
optimized in the vulnerable elderly population.
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OBJECTIVES: The US Food and Drug Administration (FDA) requires drug manufac-
turers to implement Risk Evaluation and Mitigation Strategies (REMS) to ensure
drug benefits outweigh their risks. REMS for opioids target abuse, misuse, addic-
tion, and overdose deaths. This study aims to identify which among these REMS-
designated risk categories contribute most to societal burden, where burden is the
product of prevalence (or rate for death) and per-event cost. This study also exam-
ines opioid diversion risk as a non-REMS secondary outcome.METHODS: Based on
systematic review and meta-analysis, we estimated opioid-related mortality and
prevalence for other outcomes. For outcomes other than death, we estimated
health care costs per occurrence as documented by the Healthcare Cost and Utili-
zation Project (HCUP) dataset. We focused on the value people place on avoiding
death, rather than on the health care resources consumed. As such, we estimated
the cost of each death using the Environmental Protection Agency’s value of a
statistical life (VSL), which reflects willingness to pay to avoid mortality risks.
RESULTS: Excluding populations at high-risk for adverse behaviors, prevalence
rateswere 6% to 38% formisuse, 6% to 15% for abuse, 0.3% to 0.4% for addiction, and
9% to 20% for diversion. Mortality varied widely, ranging from 1 to 108 per 100,000
person years. Treatment costs per occurrence were $8,300 for abuse, $7,400 for
addiction, and $10,000 for diversion. Misuse had no documented treatment costs.
EPA’s VSL is $7.9 million. CONCLUSIONS: Based on prevalence and per occurrence
health care costs, abuse and diversion pose the greatest societal burden, but these
findings require verification due in part to design differences across studies and
differences among populations investigated.
PODIUM SESSION I:
IMPORTANCE OF SELECTION BIAS IN HEALTH CARE RESEARCH
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OBJECTIVES: To comparemedical care consumption between duloxetine initiators
and pregabalin initiators among fibromyalgia patients.METHODS:Weconducted a
retrospective cohort study based on a US national commercial claims database
(20062009). Fibromyalgia patients who initiated duloxetine or pregabalin in 2008,
age 18 to 64, andmaintained continuous health insurance coverage one year before
and one year after initiation were assigned to duloxetine or pregabalin cohorts
based on their initiated agent. Patients with pill coverage of the agents over last 90
pre-initiation days, with less than 30 supply days of the agents in the follow-up
year, or with a diagnosis of depression, anxiety, DPNP, epilepsy or post-herpetic-
neuralgia before the initiation were excluded. Fibromyalgia-related medical care
consumption (inpatient, outpatient, medication utilization) was compared be-
tween the two cohorts. Bootstrapping and propensity score stratification methods
were used to adjust for distribution bias as well as cross-cohort differences in
demographics, pre-index clinical and economic characteristics, and medication
history. RESULTS: Compared to pregabalin initiators (n4,838), duloxetine initia-
tors (n  3033) had a similar mean initiation age (49 years), female percentage
(89%), percentages of patients using inpatient care (11.6% vs. 11.4%), outpatient
care (100%) andmedications (92.7% vs. 92.8%) in the pre-initiation year. During the
post-initiation year, duloxetine initiators had fewer patients using fibromyalgia-
related inpatient care (2.1% vs. 3.0%, p0.05), fibromyalgia-related outpatient care
(54.0% vs. 64.3%, p0.05), specialty outpatient care (83.7% vs. 89.4%, p0.05), opi-
oids (73.5% vs. 77.1%, p0.05), and non-steroidal anti-inflammatory drugs (38.8%
vs. 41.1%, p0.05) than pregabalin initiators did. They also had fewer inpatient
admissions (0.2 vs. 0.3, p0.05), fibromyalgia-related outpatient claims (4.7 vs. 8.3,
p0.05), specialty outpatient claims (26.1 vs. 30.4, p0.05), and opioid claims (6.0 vs.
7.4, p0.05). CONCLUSIONS: Among fibromyalgia patients, duloxetine initiators
consumed less fibromyalgia-related inpatient, outpatient, and specialty outpatient
care, and had fewer post-initiation claims for opioids.
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OBJECTIVES: Conventional (on-pump) coronary artery bypass grafting (CABG) is a
surgical procedure used to restore blood flow to the cardiacmuscle in patientswith
coronary artery disease. Recently, some have suggested that an off-pump CABG
procedure has lesser post-operative morbidity and mortality. Few studies to cor-
roborate this findinghave been conducted in the elderly population. The purpose of
this studywas to compare outcomes associatedwith on-pumpand off-pumpCABG
amongMedicare beneficiaries.METHODS:A retrospective cohort study designwas
used to analyze the 5% national sample of Medicare claims data. Elderly patients
(65 years) who underwent CABG from July 1, 2006 to June 30, 2008 were identified
using ICD-9-CM codes. Outcomes were assessed (using ICD-9-CM codes) following
CABG surgery to December 31, 2008. Outcomes included acute myocardial infarc-
tion (AMI), revascularization such as percutaneous coronary intervention (PCI),
stroke, in-hospital and all-cause mortality. Propensity scores were calculated to
predict the likelihood of each individual receiving on-pump versus off-pump CABG
surgery based on patient demographics and comorbidities (identified from January
1to June 30, 2006) which were then used to match (1:1) patients in the two groups.
Conditional logistic regression was used to compare the outcomes associated with
the two procedures. RESULTS: 2,760 patients (1,380 in each group) met the inclu-
sion criteria. Patients who underwent on-pump CABG had lower odds of in-hospi-
tal mortality (OR: 0.57; 95% CI: 0.39 – 0.83) and all-cause mortality (OR: 0.69; 95% CI:
0.56 – 0.85) as compared to off-pump CABG patients. The procedures were found to
be comparable in terms of clinical outcomes including AMI, PCI and stroke.
CONCLUSIONS: This study found that in-hospital and all-cause mortality associ-
ated with on-pump CABG was lower than off-pump CABG. Further clinical trials
need to be conducted to compare the safety of on-pump versus off-pump CABG
among elderly patients.
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OBJECTIVES: To assess clinical and economic consequences attributable to loss of
seizure control in privately-insured patients with partial-onset seizures (POS).
METHODS: Health insurance claims from 58 self-insured US companies between
1999 and 2009 were analyzed. Adult patients with POS (ICD-9: 345.4x, 345.5x, or
345.7x) receiving antiepileptic drugs (AED) were selected. A retrospectivematched-
cohort design was used to classify patients into cohorts of “uncontrolled POS” (2
AED therapy changes, followed by 1 epilepsy-related inpatient/ER visit within 1
year; and  1 diagnosis of POS) and “well-controlled POS” (no AED change and no
epilepsy-related inpatient/ER visit). Patients in the well-controlled POS group were
matched 1:1 with uncontrolled POS patients via propensity score matching.
Matched cohorts were compared for healthcare resource use,morbidity, and costs.
Statistical differences between cohorts were assessed using multivariate regres-
sions, adjusted for demographics, baseline AED use, comorbidities and costs.
RESULTS: From 14,377 eligible patients, 279 with uncontrolled POS (mean
age53.4, 55.6% female) were identified and matched 1:1 with well-controlled POS
patients. Compared to the well-controlled POS group, the uncontrolled POS cohort
had significantly more hospitalizations (adjusted rate ratio [ARR] (95% confidence
interval [CI])7.01 [5.97-8.82]), longer hospital stays (ARR (95% CI)10.43 [9.69-
11.23]),more ER visits (ARR (95%CI)4.99 [4.25-5.87]), andmore frequent outpatient
visits (ARR (95% CI)1.58 [1.55-1.62]). Fractures occurred three times more often in
the uncontrolled POS group (ARR (95% CI)3.43 [2.77-4.23]), while head injuries
were twice as frequent (ARR (95%CI)2.28 [2.02-2.56]). The uncontrolled POS group
incurred nearly $15,000 increase in direct healthcare costs (adjusted cost difference
(95% CI)$14,966 [$11,695-$18,944]) versus the well-controlled group. Higher direct
costs for the uncontrolled POS group were observed consistently across prescrip-
tion drug and medical service categories. CONCLUSIONS: Uncontrolled POS was
associated with significantly higher rates of healthcare resource utilization, more
frequent occurrence of fractures and head injuries, and increased direct health
care costs.
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PROPENSITY-SCORE MATCHING (PSM) TO CONTROL FOR SELECTION BIAS IN
“REAL-WORLD” TREATMENT COMPARISONS: A CAUTIONARY TALE
CONCERNING ANTIBIOTIC THERAPY FOR INFECTIOUS DISEASE
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OBJECTIVES: In infectious disease, treatment decisions are often influenced by
concerns about antibiotic resistance, which often leads to restriction of newer
agents to sicker patients (i.e., selection bias). PSM is often used to control for this
problem in “real-world” comparisons. We examined the adequacy of PSM in a
“real-world” comparison of vancomycin versus daptomycin as treatment for com-
plicated skin and skin structure infections (cSSSI). METHODS: Using a database
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